Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Digestive System Diseases AND Gastrointestinal Symptoms AND Pain

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    77 result(s) found for: Digestive System Diseases AND Gastrointestinal Symptoms AND Pain. Displaying page 2 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2017-003307-21 Sponsor Protocol Number: 848016005-02 Start Date*: 2018-05-30
    Sponsor Name:Maastricht University
    Full Title: Tailored treatment of functional dyspepsia with nortriptyline: a multi-center double-blind placebo-controlled trial (TENDER)
    Medical condition: Functional dyspepsia (FD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000085-14 Sponsor Protocol Number: D3258C00001 Start Date*: Information not available in EudraCT
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/...
    Medical condition: Eosinophilic Gastritis and/or Gastroenteritis
    Disease: Version SOC Term Classification Code Term Level
    23.0 10017947 - Gastrointestinal disorders 10083619 Eosinophilic gastritis PT
    20.1 10017947 - Gastrointestinal disorders 10017902 Gastroenteritis eosinophilic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) NL (Completed) PL (Completed) IT (Completed) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002613-10 Sponsor Protocol Number: STW5/212-D-011-III-V Start Date*: 2012-11-29
    Sponsor Name:Steigerwald Arzneimittelwerk GmbH
    Full Title: A double-blind, randomised, placebo-controlled study on the efficacy of Iberogast® (STW 5) in patients with irritable bowel syndrome
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002254-86 Sponsor Protocol Number: NAT-19/GPX Start Date*: 2022-09-26
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at l...
    Medical condition: idiopathic or diabetic gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    20.1 10017947 - Gastrointestinal disorders 10021227 Idiopathic gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) LV (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000245-12 Sponsor Protocol Number: Repha_1436 Start Date*: 2020-01-20
    Sponsor Name:Repha GmbH
    Full Title: Controlled clinical trial to evaluate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type ir...
    Medical condition: A confirmed diagnosis of irritable bowel syndrome (IBS-D or IBS-M) by a specialist in gastroenterology and/or internal medicine and/or general medicine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10023002 Irritable bowel LLT
    26.0 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001226-18 Sponsor Protocol Number: M14-431 Start Date*: 2018-04-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who H...
    Medical condition: Crohn's Disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) SE (Completed) DK (Completed) AT (Completed) PT (Completed) BE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) LV (Completed) HU (Completed) DE (Completed) PL (Completed) CZ (Completed) LT (Completed) EE (Completed) ES (Completed) BG (Completed) SI (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-000214-71 Sponsor Protocol Number: NAK-03 Start Date*: 2008-07-01
    Sponsor Name:Laboratorios Menarini S.A. (Menarini Group)
    Full Title: Double blind, randomized, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of MEN15596 in irritable bowel syndrome.
    Medical condition: Irritable Bowel Syndrome.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023003 Irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) SK (Completed) LV (Completed) DE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000324-17 Sponsor Protocol Number: GA18/118305 Start Date*: 2019-08-02
    Sponsor Name:University of Leeds
    Full Title: Amitriptyline at Low-dose and Titrated for Irritable Bowel Syndrome as Second-line Treatment (The ATLANTIS study): A Double-blind Placebo-controlled Trial
    Medical condition: Irritable Bowel Syndrome (IBS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002394-22 Sponsor Protocol Number: RFIB3053 Start Date*: 2013-09-26
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhoea (IBS-D)
    Medical condition: Irritable bowel syndrome (IBS) is a heterogeneous gastrointestinal (GI) disorder characterized by frequent and debilitating symptoms (e.g. diarrhoea, bloating, abdominal pain, urgency to defecate, ...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002751-19 Sponsor Protocol Number: 82160 Start Date*: 2023-04-11
    Sponsor Name:Amsterdam UMC
    Full Title: FAPi-PET imaging of in vivo fibrosis in inflammatory bowel disease patients
    Medical condition: Inflammatory Bowel Diseases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000307-32 Sponsor Protocol Number: Repha_1439 Start Date*: 2020-05-12
    Sponsor Name:Repha GmbH
    Full Title: Clinical trial for examination of efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrom (IBS-D)
    Medical condition: Confirmed diagnosis of diarrhea-dominant irritable bowel syndrome (IBS-D) by a specialist physician and/or internal medicine and/or general medicine
    Disease: Version SOC Term Classification Code Term Level
    26.0 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001743-78 Sponsor Protocol Number: 2011CBO/001 Start Date*: 2011-10-26
    Sponsor Name:Laves-Arzneimittel GmbH
    Full Title: MULTICENTRIC RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND 3-ARM PIVOTAL STUDY ON EFFICACY AND SAFETY OF COLIBIOGEN® ORAL IN PATIENS WITH PROVEN DIAGNOSIS OF IRRITABLE BOWEL SYNDROME
    Medical condition: Irritable bowel syndrom
    Disease: Version SOC Term Classification Code Term Level
    19.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001987-24 Sponsor Protocol Number: D3820C00004 Start Date*: 2011-08-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)
    Medical condition: Opioid-induced constipation (OIC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000894-56 Sponsor Protocol Number: NAK-06 Start Date*: 2014-02-26
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: A 12-week double-blind, randomised, placebo-controlled, parallel group phase III study, followed by a 4-week randomised withdrawal period to evaluate the efficacy and safety of oral ibodutant 10 mg...
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D) in female patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    18.0 100000004856 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) IT (Completed) DE (Completed) ES (Completed) GB (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-000895-14 Sponsor Protocol Number: NAK-07 Start Date*: 2014-01-27
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: A 52-week, double-blind, randomised, placebo-controlled, parallel-group phase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in f...
    Medical condition: Irritable bowel syndrome with diarrhoea (IBS-D) in female patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    18.0 100000004856 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Prematurely Ended) SE (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002594-33 Sponsor Protocol Number: TZP-102-CL-G003 Start Date*: 2011-10-14
    Sponsor Name:Tranzyme, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP 102 for the Treatment of Symptoms Associated w...
    Medical condition: The medical condition to be investigated is symptomatic gastroparesis due to diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10018043 Gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed) DE (Completed) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000176-41 Sponsor Protocol Number: 341-201-00004 Start Date*: Information not available in EudraCT
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Trial to Assess the Efficacy and Safety of Orally Administered OPS-2071 for 12 Weeks in Subjects With Crohn’s ...
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) PL (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004217-26 Sponsor Protocol Number: CSUC-01/16 Start Date*: 2017-04-21
    Sponsor Name:InDex Pharmaceuticals AB
    Full Title: A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients
    Medical condition: Moderate to Severe left-sided Active Ulcerative Colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SE (Completed) ES (Completed) CZ (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001986-41 Sponsor Protocol Number: D3820C00005 Start Date*: 2012-02-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)
    Medical condition: Opioid-induced constipation (OIC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed) BE (Completed) ES (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002143-15 Sponsor Protocol Number: RLM-MD-03 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) LV (Prematurely Ended) HU (Completed) FR (Completed) BE (Completed) DK (Prematurely Ended) BG (Completed) AT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 11:09:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA